A new drug application is planned for early 2025 for the indications ... PONVORY has a potential utility in the treatment of other autoimmune disorders. In plaque psoriasis, PONVORY has shown ...

AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

Guo Guangchang, Chairman of Fosun International, remarked, "Over the past seven years, CIIE has improved every year, becoming a window for China to build a new development framework, a platform for ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

By AUT Journalism Student Vivek Panchal The Government has announced it will increase funding for Pharmac, boosting ...

Selarsdi (ustekinumab-aekn), a biosimilar to Stelara (ustekinumab), is expanded to the indications to include treatment of Crohn disease.

A serendipitous discovery may lead to a new way of fighting cancer – even tumors that are resistant to immunotherapy – by ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Organon (OGN) stock on watch as FDA delays a potential label expansion for its VTAMA cream, impacting 2025 EBITDA margin and ...

Researchers from University’s Centre for Drug Safety Science (CDSS) have signed a memorandum of understanding (MOU) to establish a joint research centre with colleagues at the Shandong Provincial ...